BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15099868)

  • 1. First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome?
    Kabili G; Stricker R; Stricker R; Extermann P; Bischof P
    Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):35-8. PubMed ID: 15099868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A.
    Tul N; Pusenjak S; Osredkar J; Spencer K; Novak-Antolic Z
    Prenat Diagn; 2003 Dec; 23(12):990-6. PubMed ID: 14663836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
    Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
    Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21.
    Sahota DS; Leung TY; Fung TY; Chan LW; Law LW; Lau TK
    Ultrasound Obstet Gynecol; 2009 Apr; 33(4):387-93. PubMed ID: 19306471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First trimester maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
    Savvidou MD; Syngelaki A; Muhaisen M; Emelyanenko E; Nicolaides KH
    BJOG; 2012 Mar; 119(4):410-6. PubMed ID: 22324916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
    Herraiz I; López-Jiménez EA; García-Burguillo A; Nieto O; Villar OP; Escribano D; Galindo A
    Ultrasound Obstet Gynecol; 2009 May; 33(5):518-23. PubMed ID: 19402101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
    Wright D; Abele H; Baker A; Kagan KO
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
    Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
    Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome.
    Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM
    Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies.
    Spencer K
    Prenat Diagn; 2001 Jun; 21(6):445-7. PubMed ID: 11438946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.